CK2.1, a bone morphogenetic protein receptor type Ia mimetic peptide, repairs cartilage in mice with destabilized medial meniscus
Open Access
- 18 April 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Stem Cell Research & Therapy
- Vol. 8 (1), 1-11
- https://doi.org/10.1186/s13287-017-0537-y
Abstract
Osteoarthritis (OA) of the knee involves degeneration of articular cartilage of the diarthrodial joints. Current treatment options temporarily relieve the joint pain but do not restore the lost cartilage. We recently designed a novel bone morphogenetic protein receptor type I (BMPRI) mimetic peptide, CK2.1, that activates BMPRIa signaling in the absence of bone morphogenetic protein (BMP). Our previous research demonstrated that CK2.1 induced chondrogenesis in vitro and in vivo; however, it is unknown if CK2.1 restores damaged articular cartilage in vivo. In this study, we demonstrate that CK2.1 induced articular cartilage (AC) repair in an OA mouse model. We designed hyaluronic acid (HA)-based hydrogel particles (HGPs) that slowly release CK2.1. HGP-CK2.1 particles were tested for chondrogenic potency on pluripotent mesenchymal stem cells (C3H10T1/2 cells) and locally injected into the intra-articular capsule in mice with cartilage defects. C57BL/6J mice were operated on to destabilize the medial meniscus and these mice were kept for 6 weeks after surgery to sustain OA-like damage. Mice were then injected via the intra-articular capsule with HGP-CK2.1; 4 weeks after injection the mice were sacrificed and their femurs were analyzed for cartilage defects. Immunohistochemical analysis of the cartilage demonstrated complete repair of the AC compared to sham-operated mice. Immunofluorescence analysis revealed collagen type IX production along with collagen type II in the AC of mice injected with HGP-CK2.1. Mice injected with phosphate-buffered saline (PBS) and HGP alone had greater collagen type X and osteocalcin production, in sharp contrast to those injected with HGP-CK2.1, indicating increased chondrocyte hypertrophy. Our results demonstrate that the slow release HGP-CK2.1 drives cartilage repair without the induction of chondrocyte hypertrophy. The peptide CK2.1 could be a powerful tool in understanding the signaling pathways contributing to the repair process, and also may be used as a potential therapeutic for treating degenerative cartilage diseases such as OA.Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (4 R01 AR064243)
This publication has 33 references indexed in Scilit:
- Injectable perlecan domain 1-hyaluronan microgels potentiate the cartilage repair effect of BMP2 in a murine model of early osteoarthritisBiomedical Materials, 2012
- Altered plasma membrane dynamics of bone morphogenetic protein receptor type Ia in a low bone mass mouse modelBone, 2012
- Hyaluronic acid-based hydrogels: from a natural polysaccharide to complex networksSoft Matter, 2012
- Intra-articular Hyaluronic Acid: Potential Treatment of Younger Patients with Knee Injury and/or Post-Traumatic ArthritisThe Physician and Sportsmedicine, 2011
- Inactivation of Patched1 in the Mouse Limb Has Novel Inhibitory Effects on the Chondrogenic Program*Online Journal of Public Health Informatics, 2010
- Casein Kinase 2 β-Subunit Is a Regulator of Bone Morphogenetic Protein 2 SignalingBiophysical Journal, 2010
- Hydrolytically Degradable Hyaluronic Acid Hydrogels with Controlled Temporal StructuresBiomacromolecules, 2008
- Critical role of the extracellular signal–regulated kinase–MAPK pathway in osteoblast differentiation and skeletal developmentThe Journal of cell biology, 2007
- Elevated extracellular matrix production and degradation upon bone morphogenetic protein-2 (BMP-2) stimulation point toward a role for BMP-2 in cartilage repair and remodelingArthritis Research & Therapy, 2007
- Inflammation Research Association proceedings of the sixth international conferenceInflammation Research, 1993